CY1111105T1 - Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6 - Google Patents
Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6Info
- Publication number
- CY1111105T1 CY1111105T1 CY20111100042T CY111100042T CY1111105T1 CY 1111105 T1 CY1111105 T1 CY 1111105T1 CY 20111100042 T CY20111100042 T CY 20111100042T CY 111100042 T CY111100042 T CY 111100042T CY 1111105 T1 CY1111105 T1 CY 1111105T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- disorders
- pharmaceutically acceptable
- arylsulfonyl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε νέες ενώσεις 5-(ετεροκυκλυλ)αλκυλ-Ν-(αρυλσουλφονυλ)ινδόλης τύπου (I), στα παράγωγα τους, στα στερεοϊσομερή τους, στα φαρμακευτικά αποδεκτά άλατα τους και στις φαρμακευτικά αποδεκτές συνθέσεις που τις περιέχουν. Η παρούσα εφεύρεση αναφέρεται επίσης σε μία μέθοδο για την παρασκευή των προαναφερθέντων νέων ενώσεων, των παραγώγων τους, των στερεοϊσομερών τους, των φαρμακευτικά αποδεκτών αλάτων τους και των φαρμακευτικά αποδεκτών συνθέσεων που τις περιέχουν. Αυτές οι ενώσεις είναι χρήσιμες στην αγωγή ποικίλων διαταραχών που σχετίζονται με τις λειτουργίες του υποδοχέα 5-ΗΤ6. Ιδιαιτέρως, οι ενώσεις της παρούσας εφευρέσεως είναι επίσης χρήσιμες στην αγωγή διαφόρων διαταραχών του ΚΝΣ, αιματολογικών διαταραχών, διατροφικών διαταραχών, ασθενειών που σχετίζονται με το άλγος, αναπνευστικών ασθενειών, διαταραχών του ουρογεννητικού συστήματος, καρδιαγγειακών ασθενειών και καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN45CH2007 | 2007-01-08 | ||
EP07827525A EP2114878B1 (en) | 2007-01-08 | 2007-07-26 | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111105T1 true CY1111105T1 (el) | 2015-06-11 |
Family
ID=39495814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100042T CY1111105T1 (el) | 2007-01-08 | 2011-01-13 | Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6 |
Country Status (23)
Country | Link |
---|---|
US (1) | US8470830B2 (el) |
EP (1) | EP2114878B1 (el) |
JP (1) | JP2010515674A (el) |
KR (1) | KR101103023B1 (el) |
CN (1) | CN101553467B (el) |
AT (1) | ATE491685T1 (el) |
AU (1) | AU2007343063B2 (el) |
BR (1) | BRPI0718737A2 (el) |
CA (1) | CA2670717C (el) |
CY (1) | CY1111105T1 (el) |
DE (1) | DE602007011323D1 (el) |
DK (1) | DK2114878T3 (el) |
EA (1) | EA017007B1 (el) |
ES (1) | ES2357584T3 (el) |
HK (1) | HK1132273A1 (el) |
IL (1) | IL198821A (el) |
MX (1) | MX2009006077A (el) |
NO (1) | NO341713B1 (el) |
NZ (1) | NZ577769A (el) |
PL (1) | PL2114878T3 (el) |
PT (1) | PT2114878E (el) |
WO (1) | WO2008084492A1 (el) |
ZA (1) | ZA200903600B (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
CN103304547A (zh) * | 2012-03-13 | 2013-09-18 | 中国药科大学 | 一种抗抑郁药维拉唑酮的制备方法 |
CN105916841A (zh) * | 2013-11-25 | 2016-08-31 | 诺沃根公司 | 作为抗癌药物的功能化的和取代的吲哚 |
WO2015090233A1 (en) | 2013-12-20 | 2015-06-25 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
AU2015286049B2 (en) * | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
EP3169683A4 (en) * | 2014-07-16 | 2017-11-22 | Novogen Ltd. | Functionalised and substituted indoles as anti-cancer agents |
CN116096715A (zh) * | 2020-07-06 | 2023-05-09 | 泰科根公司 | 用于精神障碍或精神增强的有益苯并噻吩组合物 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9026389D0 (en) * | 1990-12-05 | 1991-01-23 | Merck Sharp & Dohme | Therapeutic agents |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
US6316450B1 (en) | 1997-07-11 | 2001-11-13 | Smithkline Beecham P.L.C. | Compounds |
GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
MXPA01010655A (es) | 1999-04-21 | 2002-11-04 | Allelix Biopharma | Compuestos de piperidin-indol que tienen afinidad por 5-ht6. |
GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
CN1222511C (zh) * | 2000-11-02 | 2005-10-12 | 惠氏公司 | 作为5-羟色胺-6配体的1-芳基-或1-烷基磺酰基-杂环基吲哚 |
CA2433351A1 (en) | 2001-01-30 | 2002-08-08 | Eli Lilly And Company | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
US7342021B2 (en) | 2001-02-08 | 2008-03-11 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
RU2294932C2 (ru) | 2001-06-07 | 2007-03-10 | Ф.Хоффманн-Ля Рош Аг | Новые производные индола со сродством к рецептору 5-ht6 |
EP1414442A1 (en) | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
WO2003065046A2 (en) | 2002-02-01 | 2003-08-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
JP2005522432A (ja) | 2002-02-05 | 2005-07-28 | グラクソ グループ リミテッド | ニューロン成長の促進方法 |
BRPI0308696B8 (pt) | 2002-03-27 | 2021-05-25 | Axovant Sciences Gmbh | composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos |
AU2003285759B2 (en) | 2002-11-28 | 2010-01-28 | Suven Life Sciences Limited | N-arylsulfonyl-3-aminoalkoxyindoles |
AU2003292508A1 (en) | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
CA2509982C (en) * | 2002-11-28 | 2011-11-08 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
NZ540841A (en) | 2002-12-18 | 2008-08-29 | Suven Life Sciences Ltd | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
MX2008002018A (es) | 2005-08-12 | 2008-03-27 | Suven Life Sciences Ltd | Derivados de aminoaril sulfonamida como ligandos funcionales del 5-ht6. |
BRPI0712898A2 (pt) * | 2006-07-03 | 2013-01-08 | Biovitrum Ab | indàis como moduladores de 5-ht6 |
-
2007
- 2007-07-26 AT AT07827525T patent/ATE491685T1/de active
- 2007-07-26 DK DK07827525.2T patent/DK2114878T3/da active
- 2007-07-26 CN CN2007800454515A patent/CN101553467B/zh not_active Expired - Fee Related
- 2007-07-26 NZ NZ577769A patent/NZ577769A/en not_active IP Right Cessation
- 2007-07-26 PL PL07827525T patent/PL2114878T3/pl unknown
- 2007-07-26 US US12/521,967 patent/US8470830B2/en not_active Expired - Fee Related
- 2007-07-26 EA EA200970675A patent/EA017007B1/ru not_active IP Right Cessation
- 2007-07-26 BR BRPI0718737-8A2A patent/BRPI0718737A2/pt not_active Application Discontinuation
- 2007-07-26 JP JP2009544495A patent/JP2010515674A/ja active Pending
- 2007-07-26 WO PCT/IN2007/000312 patent/WO2008084492A1/en active Application Filing
- 2007-07-26 ES ES07827525T patent/ES2357584T3/es active Active
- 2007-07-26 CA CA2670717A patent/CA2670717C/en not_active Expired - Fee Related
- 2007-07-26 MX MX2009006077A patent/MX2009006077A/es active IP Right Grant
- 2007-07-26 DE DE602007011323T patent/DE602007011323D1/de active Active
- 2007-07-26 AU AU2007343063A patent/AU2007343063B2/en not_active Ceased
- 2007-07-26 PT PT07827525T patent/PT2114878E/pt unknown
- 2007-07-26 EP EP07827525A patent/EP2114878B1/en active Active
- 2007-07-26 KR KR1020097011686A patent/KR101103023B1/ko active IP Right Grant
-
2009
- 2009-05-19 IL IL198821A patent/IL198821A/en active IP Right Grant
- 2009-05-25 ZA ZA200903600A patent/ZA200903600B/xx unknown
- 2009-05-27 NO NO20092067A patent/NO341713B1/no not_active IP Right Cessation
- 2009-12-29 HK HK09112256.5A patent/HK1132273A1/xx not_active IP Right Cessation
-
2011
- 2011-01-13 CY CY20111100042T patent/CY1111105T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
MX2009006077A (es) | 2009-06-17 |
IL198821A0 (en) | 2010-02-17 |
CA2670717C (en) | 2012-01-10 |
DK2114878T3 (da) | 2011-03-14 |
AU2007343063B2 (en) | 2011-02-17 |
ATE491685T1 (de) | 2011-01-15 |
BRPI0718737A2 (pt) | 2014-03-25 |
CN101553467A (zh) | 2009-10-07 |
EA200970675A1 (ru) | 2009-12-30 |
US20100041673A1 (en) | 2010-02-18 |
EP2114878B1 (en) | 2010-12-15 |
WO2008084492A1 (en) | 2008-07-17 |
CN101553467B (zh) | 2011-12-07 |
CA2670717A1 (en) | 2008-07-17 |
EP2114878A1 (en) | 2009-11-11 |
EA017007B1 (ru) | 2012-09-28 |
ES2357584T3 (es) | 2011-04-27 |
NO341713B1 (no) | 2018-01-08 |
NO20092067L (no) | 2009-09-04 |
JP2010515674A (ja) | 2010-05-13 |
ZA200903600B (en) | 2010-07-28 |
NZ577769A (en) | 2011-01-28 |
AU2007343063A1 (en) | 2008-07-17 |
PT2114878E (pt) | 2011-03-10 |
KR101103023B1 (ko) | 2012-01-05 |
DE602007011323D1 (de) | 2011-01-27 |
US8470830B2 (en) | 2013-06-25 |
KR20090080544A (ko) | 2009-07-24 |
PL2114878T3 (pl) | 2011-05-31 |
AU2007343063A8 (en) | 2009-07-23 |
HK1132273A1 (el) | 2010-02-19 |
IL198821A (en) | 2014-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111105T1 (el) | Ενωσεις 5-(ετεροκυκλυλ)αλκυλ-ν-(αρυλσουλφονυλ)ινδολης και η χρηση τους ως προσδεματα του 5-ητ6 | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten | |
MD3265459T2 (ro) | Compuși amidici în calitate de agoniști ai receptorilor 5-HT4 | |
CY1111836T1 (el) | Ενωσεις aminoalkoxy aryl sulfonamide και η χρηση τους σαν συνδετων (ligands) 5-ητ6 | |
ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
MX2009006757A (es) | Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6. | |
CY1112181T1 (el) | Αμινο αρυλοσουλφοναμιδικες ενωσεις και η χρηση τους ως 5-ητ6 συνδετες | |
BR112014006675A2 (pt) | derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide | |
MX2016007857A (es) | Compuestos de indazol como agonistas del receptor de 5-ht4. |